OCT3/4 enhances tumor immune response by upregulating the TET1-dependent NRF2/MDM2 axis in bladder cancer-Reference-Cited by-同舟云学术

OCT3/4 enhances tumor immune response by upregulating the TET1-dependent NRF2/MDM2 axis in bladder cancer

Published:2021-07 Issue:4 Volume:113 Page:2122-2133
ISSN:0888-7543
Container-title:Genomics
language:en
Short-container-title:Genomics

Author:

Mao Minghuan,Yang Liang,Hu Jingyao,Liu Bing,Liu Chunlai,Zhang Xiling,Liu Yili,Wang Ping,Li Hangyu

Publisher

Elsevier BV

Subject

Genetics

Reference29 articles.

1. Epidemiology, incidence and mortality of bladder cancer and their relationship with the development index in the world;Mahdavifar;Asian Pac. J. Cancer Prev.,2016

2. Epidemiology of and risk factors for bladder cancer and for urothelial tumors;Guillaume;Rev Prat,2014

3. Epidemiology, aetiology and screening of bladder cancer;Cumberbatch;Transl Androl Urol,2019

4. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis;Liu;Minerva Urol. Nefrol.,2020

5. Perioperative nutrition for the treatment of bladder cancer by radical cystectomy: a Cochrane review summary;Pich;Int. J. Nurs. Stud.,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy;Journal of Biomedical Science;2024-01-29

2. Modulation of NRF2: Biological Dualism in Cancer, Targets and Possible Therapeutic Applications;Antioxidants & Redox Signaling;2023-09-06

3. E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies;Frontiers in Immunology;2023-07-11

4. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients;Frontiers in Immunology;2023-05-30

5. The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy;Frontiers in Immunology;2023-05-05